Nabla Bio

Company profile

About Nabla Bio

Nabla Bio is transforming drug development from trial-and-error into a true design discipline by integrating generative AI with human-relevant biological testing. At the core of their platform is JAM, a multimodal generative modeling system trained on massive protein sequence and structure data, strengthened with Nabla-generated measurements from mammalian systems. JAM can design antibodies and biologics de novo by taking partial molecular context—such as a disease target or epitope—and generating complete, developable molecules with drug-like properties from the start. The company's integrated approach combines computational design with experimental validation at scale, producing thousands of protein designs and measuring binding, developability properties, and function in cellular and in vivo contexts that closely reflect human biology. This enables parallel de novo antibody design campaigns, generative design of multispecific therapeutics, and the ability to drug previously inaccessible targets like GPCRs, ion channels, and transporters. Based in Cambridge, Massachusetts, Nabla Bio partners with leading pharmaceutical companies to embed their platform across discovery pipelines and licenses designed biologics for development. Their technology addresses fundamental challenges in biologics development including epitope-specific targeting, developability optimization, and the design of complex multispecific architectures that maintain binding affinity while avoiding aggregation and misfolding.

Company description · Nabla Bio official website